Expansion momentum Nemera is actively expanding manufacturing footprint in Europe with new production halls in La Verpillière, France and Szczecin, Poland, signaling capacity growth and potential for increased contract manufacturing of drug delivery devices.

Diversified delivery platforms With capabilities spanning ophthalmic, nasal and buccal, inhalation, dermal, transdermal, and parenteral devices, Nemera offers integrated, end-to-end solutions that can align with customers seeking multi-route, single-vendor drug delivery programs.

Strategic partnerships Recent collaborations with Therakind and integration with SCHOTT Pharma suggest Nemera’s openness to co-development and preferred-provider arrangements, creating opportunities for joint development, technology licensing, and integrated pen injector or nasal spray platforms.

Innovation pipeline Launch of the DuoSpray bi-dose nasal platform and development of DriDose dry powder intranasal technology indicate a strong focus on needle-free, patient-friendly delivery methods, appealing to customers targeting needle-free therapies and improved adherence.

Customer-centric credibility Nemera’s emphasis on patient-first design, quality manufacturing, and early device strategy support positions them as a trusted partner for pharmaceutical companies seeking reliable, compliant device solutions to accelerate time-to-market.